RESUMEN
BACKGROUND/OBJECTIVES: Visceral adipose tissue (VAT) mass, a risk factor for cardiometabolic complications of obesity, is usually measured by magnetic resonance imaging (MRI) but this method is not practical in a clinical setting. In contrast, measurement of VAT by dual-x-ray absorptiometry (DXA) appears to circumvent the limitations of MRI. In this study, we compared measurements of VAT mass by MRI and DXA in the large, multiethnic cohort of the Dallas Heart Study (DHS). SUBJECTS/METHODS: About 2689 DHS participants underwent paired measurement of VAT by MRI and DXA. Sex-stratified analyses were performed to evaluate the correlation and agreement between DXA and MRI. Model validation was performed using bootstrapping and inter-reader variability was assessed. RESULTS: Mean age of the cohort was 44 years, with 55% female, 48% Black and 75% overweight/obese participants. Regression analysis showed a linear relationship between DXA and MRI with R(2)=0.82 (95% confidence interval (CI) 0.81-0.84) for females and R(2)=0.86 (95% CI 0.85-0.88) for males. Mean difference between methods was 0.01 kg for females and 0.09 kg for males. Bland-Altman analysis showed that DXA tended to modestly underestimate VAT compared with MRI at lower VAT levels and overestimate it compared with MRI at higher VAT levels. Results were consistent in analyses stratified by race, body mass index status, waist girth and body fat. Inter-individual reader correlation among 50 randomly selected scans was excellent (inter-class correlation coefficient=0.997). CONCLUSIONS: VAT mass quantification by DXA was both accurate and valid among a large, multiethnic cohort within a wide range of body fatness. Further studies including repeat assessments over time will help determine its long-term applicability.
Asunto(s)
Absorciometría de Fotón , Grasa Intraabdominal/diagnóstico por imagen , Obesidad/diagnóstico por imagen , Adulto , Negro o Afroamericano , Composición Corporal/fisiología , Índice de Masa Corporal , Femenino , Hispánicos o Latinos , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Población BlancaRESUMEN
AIMS/HYPOTHESIS: Plasma levels of adiponectin are inversely associated with body mass. We hypothesised that adipose tissue distribution and body composition influences adiponectin levels. METHODS: We assessed plasma adiponectin concentrations and dual-energy X-ray absorptiometry (DEXA) measurements of body composition among 2,820 participants from the Dallas Heart Study. RESULTS: Among both women and men, adiponectin levels were higher in whites than in either Hispanics or African-Americans (for women: median 9.99 µg/ml [25th,75th percentile 7.11, 13.77] vs 7.56 µg/ml [5.05, 9.98] vs 6.39 µg/ml [4.37, 9.41], respectively, p < 0.0001; for men: 6.43 µg/ml [4.66, 9.19] vs 5.55 µg/ml [3.64, 7.50] vs 5.03 µg/ml [3.39, 7.28], p < 0.0001). In univariate analysis, each individual component of body mass was inversely associated with adiponectin. After multivariate analysis, adiponectin levels were found to be positively associated with lower extremity fat, whether expressed in absolute mass (for women: ß = 0.055, p < 0.0001; for men: ß = 0.061, p < 0.0001), or as a relative proportion (for women: ß = 0.035, p < 0.0001; for men: ß = 0.034, p < 0.0001). This association was consistent across ethnicities. Conversely, adiponectin was negatively correlated with truncal fat, both in absolute (for women: ß = -0.039, p < 0.0001; for men: ß = -0.044, p < 0.0001) and relative terms (for women: ß = -0.027, p < 0.0001; for men ß = -0.033, p < 0.0001). At the extreme of body mass, higher degrees of lower extremity and truncal adiposity were associated with higher levels of adiponectin. CONCLUSIONS/INTERPRETATION: These data suggest that the location of adipose depots differentially influences circulating adiponectin concentrations-a finding observed across ethnicity and sex. Gross measures of body mass alone do not adequately account for adiponectin levels. This supports a role of adiponectin as a mediator of the positive effects of lower extremity adiposity on improvements in insulin sensitivity.
Asunto(s)
Adiponectina/sangre , Tejido Adiposo/metabolismo , Absorciometría de Fotón , Adiposidad/fisiología , Adulto , Composición Corporal/fisiología , Índice de Masa Corporal , Peso Corporal/fisiología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Obesidad/sangre , Obesidad/metabolismo , Adulto JovenRESUMEN
OBJECTIVE: The aim of this study was to evaluate the influence of ageing and body mass index (BMI) on the revised National Cholesterol Education Program (NCEP)-defined metabolic syndrome, its components, diabetes and coronary heart disease prevalence using the Third National Health and Nutrition Examination Survey. METHODS: Data from adults aged 20 and older who received morning physical examinations after a fast of at least 9 h (n = 7959), representing 196.8 million Americans were used in this analysis. The population was stratified by age deciles and BMI categories using standard definitions of overweight and obesity. Due to small sample size, those few individuals with BMI <18.5 were excluded. RESULTS: Fasting glucose, diabetes and systolic blood pressure (SBP) seem to have a linear relationship with age and BMI, that is, increasing BMI seems to linearly reduce the age decile when the mean exceeds the NCEP cutpoint. Regardless of BMI, the prevalence of diabetes and hypertension increases with age. Triglyceride levels and prevalence of metabolic syndrome follow a pattern that is less linear. Fasting insulin and C-reactive protein (CRP) levels correlate better with BMI than age. Diastolic BP and HDL cholesterol for men and women (analysed separately) did not correlate with either age or BMI. CONCLUSION: For each component of the metabolic syndrome and associated factors, there is a complex interaction between ageing and obesity. Some components are associated with obesity but not ageing (e.g. CRP), while others are associated with both obesity and ageing (e.g. glucose). Even when the association exists, the specific relationship can appear to be more (e.g. SBP) or less (e.g. triglycerides) linear.
Asunto(s)
Factores de Edad , Índice de Masa Corporal , Síndrome Metabólico/etiología , Obesidad/complicaciones , Adulto , Anciano , Anciano de 80 o más Años , Glucemia/metabolismo , Presión Sanguínea/fisiología , HDL-Colesterol/metabolismo , Diabetes Mellitus/metabolismo , Ayuno/sangre , Ayuno/metabolismo , Femenino , Humanos , Masculino , Síndrome Metabólico/metabolismo , Persona de Mediana Edad , Obesidad/metabolismoRESUMEN
Coronary artery disease (CAD) and dyslipidemia have strong genetic components. Heterogeneity complicates evaluating genetics of complex diseases such as CAD; incorporating disease-related phenotypes may help reduce heterogeneity. We hypothesized that incorporating lipoproteins in a study of CAD would increase the power to map genes, narrow linkage peaks, identify phenotypic subsets, and elucidate the contribution of established risk factors to genetic results. We performed ordered subset analysis (OSA) and quantitative trait linkage (QTL) using serum lipoproteins and microsatellite markers in 346 families with early-onset CAD. OSA defined homogeneous subsets and calculated lod scores across a chromosome after ranking families by mean lipoprotein values. QTL used variance components analysis. We found significantly increased linkage to chromosome 3q13 (LOD 5.10, p = 0.008) in families with higher HDL cholesterol, lower LDL and total cholesterol, lower triglycerides, and fewer CAD risk factors, possibly due to a concentrated non-lipoprotein-related genetic effect. OSA identified linkage on chromosome 5q34 in families with higher cholesterol, possibly representing a hereditary lipoprotein phenotype. Multiple QTLs were identified, with the strongest for: total cholesterol on chromosome 5q14 (LOD 4.3); LDL on 20p12 (LOD 3.97); HDL on 3p14 (LOD 1.65); triglycerides on 18q22 (LOD 1.43); and HDL/TC ratio on 3q27-28 (LOD 2.06). Our findings suggest the presence of etiologic heterogeneity in families with early-onset CAD, potentially due to differential effects of lipoprotein phenotypes. Candidate genes are under investigation.
Asunto(s)
Cromosomas Humanos Par 3 , Cromosomas Humanos Par 5 , Enfermedad de la Arteria Coronaria/genética , Lipoproteínas/sangre , Sitios de Carácter Cuantitativo , Adulto , Enfermedad de la Arteria Coronaria/diagnóstico , Femenino , Ligamiento Genético , Variación Genética , Humanos , Lipoproteínas/genética , Escala de Lod , Masculino , Persona de Mediana Edad , FenotipoRESUMEN
Representatives from five international organizations (International Society of Nephrology, World Heart Federation, International Diabetes Federation, International Atherosclerosis Federation, and International Society of Hypertension) participated in a strategic planning workshop in December 2005 in Bellagio, Italy sponsored by the Rockefeller Foundation. There were equal representatives from developed and developing countries. Global perspectives on diabetes and cardiovascular and renal diseases were presented, with special emphasis on China, India, Latin America, and Africa. The rationale and effectiveness of preventive measures were discussed. It was apparent that measures for primary prevention and early intervention for all the chronic vascular diseases are similar. The five organizations agreed that an integrated global approach to chronic vascular diseases is needed. They resolved to collaborate and work towards an integrated approach to chronic vascular diseases with the establishment of a 5-year plan for the prevention and treatment of chronic vascular diseases, including public advocacy, advising international and national agencies, and improving education and the practice of established approaches.
Asunto(s)
Complicaciones de la Diabetes/prevención & control , Salud Global , Agencias Internacionales/tendencias , Enfermedades Vasculares/prevención & control , Enfermedad Crónica , Países Desarrollados , Países en Desarrollo , Diabetes Mellitus/prevención & control , Accesibilidad a los Servicios de Salud , Humanos , Cooperación Internacional , Italia , Enfermedades Renales/prevención & control , Defensa del Paciente , Factores de RiesgoRESUMEN
The metabolic syndrome is a constellation of metabolic risk factors for atherosclerotic cardiovascular disease (ASCVD) occurring in one individual. There are five cardiovascular risk factors that accompany the metabolic syndrome: atherogenic dyslipidemia [elevated apolipoprotein B (apo B), elevated triglyceride, small low-density lipoprotein (LDL) particles, and low high-density lipoprotein (HDL)cholesterol], elevated blood pressure, elevated glucose, a prothrombotic state, and a proinflammatory state. The likelihood of an individual developing metabolic syndrome is enhance by underlying risk factors, notably, obesity, insulin resistance, lack of physical activity, advancing age, and hormonal factors (e.g., androgens and corticosteroids). Besides being at higher risk for ASCVD, persons with the metabolic syndrome are at increased risk for type 2 diabetes. Persons with the metabolic syndrome deserve management in the clinical setting to reduce the risk for both ASCVD and type 2 diabetes. The two major therapeutic strategies for treatment of affected persons are modification of the underlying risk factors and separate drug treatment of the particular metabolic risk factors when appropriate. First-line therapy for underlying risk factors is therapeutic lifestyle changes, i.e., weight loss in obese persons, increased physical activity, and anti-atherogenic diet. These changes will improve all of the metabolic risk factors. Whether use of drugs to reduce insulin resistance is effective, safe, and cost-effective before the onset of diabetes awaits the results of more clinical research. Turning to individual risk components, for atherogenic dyslipidemia, drug therapies that promote lowering of apo B and raise HDL cholesterol will be needed for higher risk patients. Treatment of categorical hypertension with drugs has become standard practice. When hyperglycemia reaches the diabetic level, glucose-lowering agents will become necessary when dietary control is no longer effective, and reduction of a prothrombotic state with low-dose aspirin may be indicated in higher-risk patients.
Asunto(s)
Síndrome Metabólico/terapia , Aterosclerosis/etiología , Glucemia/análisis , Proteína C-Reactiva/análisis , Dislipidemias/complicaciones , Humanos , Hipertensión/complicaciones , Síndrome Metabólico/sangre , Síndrome Metabólico/diagnóstico , Síndrome Metabólico/etiología , Obesidad/complicaciones , Factores de RiesgoAsunto(s)
Arteriosclerosis/complicaciones , Arteriosclerosis/prevención & control , Cardiología/métodos , Enfermedades Cardiovasculares/etiología , Enfermedades Cardiovasculares/prevención & control , Infarto del Miocardio/etiología , Infarto del Miocardio/prevención & control , Cardiología/normas , Enfermedades Cardiovasculares/mortalidad , Complicaciones de la Diabetes , Diabetes Mellitus/prevención & control , Medicina Basada en la Evidencia , Ejercicio Físico , Humanos , Hiperlipidemias/complicaciones , Hiperlipidemias/prevención & control , Hipertensión/complicaciones , Hipertensión/prevención & control , Estilo de Vida , Infarto del Miocardio/mortalidad , Obesidad/complicaciones , Obesidad/prevención & control , Prevención Primaria/métodos , Prevención Primaria/normas , Factores de Riesgo , Fumar/efectos adversos , Prevención del Hábito de FumarAsunto(s)
Enfermedad Coronaria/prevención & control , Técnicas de Diagnóstico Cardiovascular , Anciano , American Heart Association , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Aspirina/uso terapéutico , Presión Sanguínea , Enfermedades de las Arterias Carótidas/diagnóstico por imagen , Enfermedad Coronaria/diagnóstico , Técnicas de Apoyo para la Decisión , Electrocardiografía , Prueba de Esfuerzo , Femenino , Conductas Relacionadas con la Salud , Humanos , Masculino , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Pronóstico , Medición de Riesgo , Factores de Riesgo , Tomografía Computarizada por Rayos X , UltrasonografíaRESUMEN
The new clinical guidelines of the US National Cholesterol Education Program (NCEP) were released in May 2001. These guidelines were published as the NCEP's Adult Treatment Panel (ATP) III report. They are derived from an extensive review of the emerging literature so as to provide an evidence-based report. Thanks to recent clinical trials of cholesterol-lowering therapy, it is possible to expand the scope of clinical management for both dietary and drug therapies. This expansion derives from a conclusive demonstration of efficacy, safety, and cost-effectiveness of therapies. This article will review briefly the major features of ATP III.
Asunto(s)
Anticolesterolemiantes/uso terapéutico , LDL-Colesterol/sangre , Enfermedad de la Arteria Coronaria/tratamiento farmacológico , Ácidos Heptanoicos/uso terapéutico , Hipercolesterolemia/tratamiento farmacológico , Guías de Práctica Clínica como Asunto , Pirroles/uso terapéutico , Adulto , Atorvastatina , Colesterol en la Dieta/administración & dosificación , Colesterol en la Dieta/efectos adversos , Ensayos Clínicos como Asunto , Enfermedad de la Arteria Coronaria/sangre , Humanos , Hipercolesterolemia/sangreAsunto(s)
Arteriosclerosis/complicaciones , Enfermedades Cardiovasculares/complicaciones , Muerte Súbita Cardíaca/prevención & control , Paro Cardíaco/prevención & control , American Heart Association , Muerte Súbita Cardíaca/etiología , Paro Cardíaco/etiología , Humanos , Guías de Práctica Clínica como Asunto , Medicina Preventiva/normas , Rehabilitación/normas , Estados UnidosAsunto(s)
Enfermedad Coronaria/etiología , Grasas de la Dieta/efectos adversos , Ácidos Grasos/efectos adversos , Ensayos Clínicos Controlados como Asunto , Enfermedad Coronaria/epidemiología , Grasas de la Dieta/administración & dosificación , Grasas Insaturadas en la Dieta/administración & dosificación , Ácidos Grasos/administración & dosificación , Humanos , Lipoproteínas LDL/sangreAsunto(s)
Enfermedades Cardiovasculares/prevención & control , Adulto , Factores de Edad , Anciano , Presión Sanguínea , Enfermedades Cardiovasculares/complicaciones , Colesterol/sangre , Estudios de Cohortes , Enfermedad Coronaria/complicaciones , Enfermedad Coronaria/prevención & control , Complicaciones de la Diabetes , Femenino , Humanos , Hipertensión/complicaciones , Masculino , Persona de Mediana Edad , National Institutes of Health (U.S.) , Factores de Riesgo , Fumar , Estados UnidosRESUMEN
For the past 40 y the scientific community has decried the inadequacy of the training of physicians and other health professionals in the subject of human nutrition. In 1997 the National Heart, Lung, and Blood Institute developed the Nutrition Academic Award (NAA) Program, an initiative to improve nutrition training across a network of US medical schools. The purpose of this funding, which began in 1998, is to support the development and enhancement of nutrition curricula for medical students, residents, and practicing physicians to learn principles and practice skills in nutrition. The NAA recipients developed the Nutrition Curricular Guide for Training Physicians, a plan to incorporate clinical guidelines into physician practice skills, create educational and assessment practice tools, and evaluate curricula, materials, and teaching tools. Dissemination of NAA activities and materials will be facilitated by a national website, presentations and publications, and consultants and advisors from the NAA nutrition education programs. The NAA Program constitutes a major new effort to enhance nutrition knowledge and skills among health care providers and to effectively apply the science of human nutrition to clinical medicine. This article describes the purpose and aims of the NAA Program, the organizational structure of the network of recipients, a profile of the recipients and individual programs at 21 medical schools, the various strategies to overcome barriers in training physicians in human nutrition, and collaborative and dissemination efforts.
Asunto(s)
Distinciones y Premios , Curriculum , Educación Médica , Ciencias de la Nutrición/educación , Competencia Clínica , Conocimientos, Actitudes y Práctica en Salud , Humanos , Facultades de Medicina , Estudiantes de Medicina , Estados UnidosRESUMEN
Risk assessment is assuming an increasing role for identification of high-risk persons for intensive medical intervention to reduce risk for coronary heart disease (CHD). Of particular importance is the need to identify those persons with CHD risk equivalents who can be managed with the same intensity as patients with established CHD. For example, the National Cholesterol Education Program (NCEP) recently classified diabetes as a CHD risk equivalent. The NCEP also recommended use of Framingham risk scoring in persons with multiple (2+) risk factors to uncover others without diabetes who have CHD risk equivalents. One limitation of Framingham risk scoring, however, is that age becomes the dominant risk factor after age 50. Age is a surrogate for coronary atherosclerotic plaque burden, which is the true risk factor. However, for individuals, coronary plaque burden can vary greatly at any given age. For this reason, if coronary plaque burden could be measured accurately with noninvasive techniques, the degree of plaque burden could be used to replace age as a risk factor in Framingham scoring for risk prediction. This article describes a technique whereby such a replacement can be made.
Asunto(s)
Calcinosis/complicaciones , Enfermedad Coronaria , Medición de Riesgo , Adulto , Anciano , Carga Corporal (Radioterapia) , Enfermedad Coronaria/diagnóstico por imagen , Enfermedad Coronaria/etiología , Enfermedad Coronaria/patología , Enfermedad Coronaria/prevención & control , Femenino , Humanos , Masculino , Persona de Mediana Edad , UltrasonografíaAsunto(s)
Calcinosis/complicaciones , Calcinosis/diagnóstico por imagen , Enfermedad de la Arteria Coronaria/complicaciones , Enfermedad de la Arteria Coronaria/diagnóstico por imagen , Enfermedad Coronaria/etiología , Tamizaje Masivo/métodos , Medición de Riesgo/métodos , Anciano , Calcinosis/clasificación , Calcinosis/prevención & control , Enfermedad de la Arteria Coronaria/clasificación , Enfermedad de la Arteria Coronaria/prevención & control , Humanos , Tamizaje Masivo/normas , Persona de Mediana Edad , Guías de Práctica Clínica como Asunto , Valor Predictivo de las Pruebas , Prevención Primaria , Reproducibilidad de los Resultados , Medición de Riesgo/normas , Factores de Riesgo , Índice de Severidad de la Enfermedad , Tomografía Computarizada por Rayos X/métodos , Tomografía Computarizada por Rayos X/normasAsunto(s)
Antiinflamatorios/administración & dosificación , Enfermedad de la Arteria Coronaria/prevención & control , Mediadores de Inflamación/sangre , Monocitos/efectos de los fármacos , Vitamina E/administración & dosificación , Adulto , Antiinflamatorios/efectos adversos , Enfermedad de la Arteria Coronaria/inmunología , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Femenino , Humanos , Masculino , Monocitos/inmunología , Estrés Oxidativo/efectos de los fármacos , Factores de Riesgo , Vitamina E/efectos adversosRESUMEN
BACKGROUND: Prospective studies indicate that baseline levels of C-reactive protein (CRP), the prototypic marker of inflammation, are associated with an increased risk for cardiovascular events. Limited studies have examined therapies that influence high-sensitive CRP (hs-CRP) levels, especially in hyperlipidemic patients. Thus, we tested the effects of 3 hydroxymethyl glutaryl coenzyme A reductase inhibitors (statins), simvastatin (20 mg/d), pravastatin (40 mg/d), and atorvastatin (10 mg/d), on levels of hs-CRP in a randomized, double-blind, crossover trial of 22 patients with combined hyperlipidemia (LDL cholesterol >130 mg/dL and triglycerides of 200 to 600 mg/dL). METHODS AND RESULTS: After 6 weeks of an American Heart Association Step 1 diet, fasting blood samples were drawn at baseline and after 6 weeks of therapy with each drug. hs-CRP levels were significantly decreased after treatment with all 3 statins compared with baseline (median values: baseline, 2.6 mg/L; atorvastatin, 1.7 mg/L; simvastatin, 1.7 mg/L; and pravastatin, 1.9 mg/L; P<0.025). The reductions obtained with the 3 statins were similar. In addition, there was no significant effect on either plasma interleukin-6 or interleukin-6 soluble receptor levels. There was no relationship between reductions in hs-CRP and LDL cholesterol. CONCLUSIONS: Pravastatin, simvastatin, and atorvastatin significantly decreased levels of hs-CRP. These data support an anti-inflammatory effect of these drugs.